OHSONG PHARM passed  the 2nd year's performance evaluation and the 3rd year's plan of  the  Jeju Local Small Giant Company Promotion Project.
 

During the 1st year period, OHSONG PHARM make the foundation for enter into the Japanese pharmaceutical market directly.
For this period, OHSONG PHARM and BRIO PHARMA, the subsidiary of japan, got a license for manufacture and sell in Japanese medicine market.
Also, OHSONG PHARM did gap analysis of medical regulations  between Japanese and Korean.
In the 2nd year of the project, OHSONG PHARM developed a new item to enter into the Japanese market and contracted a joint development agreement with Whan-In Pharmaceutical and Daewoong Pharmaceutical.
And, in the 3rd period, OHSONG PHARM will make effort to launch some new medicines  to Japan market.
 

In particular, OHSONG PHARM could be selected as a ‘2020, Small Giant Company of Korea’ thanks to Jeju-do local government’s generous support.